Teva Pharmaceutical Indus... (TEVA)
NYSE: TEVA
· Real-Time Price · USD
17.86
0.32 (1.82%)
At close: Aug 15, 2025, 3:59 PM
17.88
0.14%
After-hours: Aug 15, 2025, 06:05 PM EDT
Teva Pharmaceutical Industries Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | n/a | 220M | -275M | -437M | -845M | -139M | 433M | 88M | -898M | -238M | -1.25B | 59M | -259M | -952M | -152M | 302M | 222M | 84M |
Depreciation & Amortization | n/a | 244M | 269M | 259M | 259M | 272M | 266M | 283M | 300M | 304M | 306M | 321M | 358M | 323M | 320M | 329M | 305M | 376M |
Stock-Based Compensation | n/a | 34M | 34M | 29M | 32M | 28M | 28M | 31M | 30M | 32M | 36M | 26M | 39M | 24M | 33M | 26M | 29M | 31M |
Other Working Capital | n/a | -700M | -245M | 317M | -10M | -497M | -421M | -600M | -167M | -323M | -341M | -168M | 354M | 254M | -1.47B | -202M | -603M | -1.55B |
Other Non-Cash Items | n/a | 103M | 760M | 1.23B | 1.96B | 1.27B | 99M | 40M | 732M | 227M | 1.48B | 931M | -107M | 172M | 208M | 66M | 249M | 191M |
Deferred Income Tax | n/a | n/a | 32M | -53M | -424M | -189M | 32M | -199M | -44M | -106M | 155M | 44M | -1.08B | -175M | -133M | 8M | 16M | -11M |
Change in Working Capital | n/a | -700M | -245M | 317M | -10M | -497M | 326M | -238M | 204M | -364M | 250M | 94M | 354M | 559M | 180M | -202M | -603M | -1.08B |
Operating Cash Flow | 227M | -105M | 575M | 693M | 420M | 171M | 1.18B | 5M | 324M | -145M | 973M | 543M | 123M | -49M | 456M | 529M | 218M | -405M |
Capital Expenditures | n/a | -127M | -129M | -148M | -97M | -124M | -119M | -149M | -119M | -139M | -142M | -122M | -127M | -157M | -153M | -146M | -113M | -150M |
Cash Acquisitions | n/a | 17M | 4M | n/a | 1M | -79M | -68M | 10M | 56M | 2M | 23M | 2M | 18M | -7M | -269M | 15M | 116M | 138M |
Purchase of Investments | n/a | -11M | -15M | -1M | -43M | -12M | -2M | -38M | -2M | -4M | 1M | 2M | n/a | -4M | -11M | 397M | -34M | -2M |
Sales Maturities Of Investments | n/a | n/a | n/a | 40M | n/a | n/a | -361M | -10M | 371M | n/a | 2M | 1M | 3M | n/a | 681M | 19M | 109M | 44M |
Other Investing Acitivies | n/a | 322M | 342M | 377M | -42M | -12M | 422M | 371M | -4M | 322M | 286M | 264M | -2M | 329M | -2M | 3M | 369M | 476M |
Investing Cash Flow | n/a | 201M | 202M | 268M | -139M | -215M | 301M | 184M | 302M | 181M | 170M | 147M | 179M | 161M | 246M | 288M | 481M | 508M |
Debt Repayment | n/a | -1.37B | -685M | n/a | -956M | n/a | -500M | -500M | n/a | -701M | -708M | -365M | -296M | n/a | -500M | -1.18B | n/a | -491M |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | -376M | 11M | n/a | -10M | -151M | -76M | -76M | -55M | -5M | -3M | -74M | -42M | 2M | -1M | -2M | -1M | -2M |
Financial Cash Flow | n/a | -1.74B | -674M | n/a | -966M | -87M | -576M | -576M | -55M | -706M | -713M | -440M | -338M | 2M | -501M | -1.18B | -1M | -493M |
Net Cash Flow | n/a | -1.6B | -19M | 1.06B | -733M | -235M | 977M | -420M | 494M | -658M | 576M | 167M | -159M | 52M | 153M | -391M | 693M | -434M |
Free Cash Flow | 227M | -232M | 446M | 545M | 323M | 47M | 1.06B | -144M | 205M | -284M | 831M | 421M | -4M | -206M | 303M | 383M | 105M | -555M |